Tech Company Financing Transactions
Zetagen Therapeutics Funding Round
On 11/26/2025, Zetagen Therapeutics raised $12 million in Series B financing from private investors.
Transaction Overview
Company Name
Announced On
11/26/2025
Transaction Type
Venture Equity
Amount
$12,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the advancement of its lead candidate: ZetaMet (Zeta-BC-003) towards commercialization,; accelerate clinical development of ZetaMast (Zeta-MBC-005); and complete preclinical studies & GMP manufacturing of ZetaPrime (Zeta-PBC-007).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
841 East Fayette Street 1100
Syracuse, NY 13210
USA
Syracuse, NY 13210
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet� technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joe Loy
Chief Financial Officer
Jess Pletka
Chief Scientific Officer
Bryan Margulies
Browse more venture capital transactions:
Prev: 11/25/2025: Overstory venture capital transaction
Next: 11/26/2025: EcoG venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs